Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.

摘要

In patients progressing on imatinib/sunitinib, cediranib 45 mg/day demonstrated evidence of activity by (18)FDG-PET, but did not reduce average SUVmax. Evidence of antitumor activity was seen in ASPS.